Share real-life insights on factors that contribute to treatment decision-making when initiating new myeloma therapies

Apply practical considerations related to dosing and administration of novel anti-BCMA therapies, including antibody-drug conjugates (ADCs), to support evidence-based, patient-centred treatment management

Demonstrate how to streamline collaboration with other healthcare professionals, with a focus on adverse event management